CMS Entry id: 2709 | Channel: Blog landing page | Template: blog/index

Login
Facebook YouTube Twitter Linkedin
Facebook YouTube Twitter Linkedin

Blog

CANTAB tests predict functional decline in patients with amnestic mild cognitive impairment

We presented a novel, predictive model of functional decline at CTAD 2018. The model suggests that CANTAB PAL and SWM provide essential screening information when recruiting patients with amnestic mild cognitive impairment into Alzheimer’s disease clinical trials.

Can digital health reduce the treatment burden on patients?

Comprehensive neuropsychological testing typically takes hours to complete, which can be mentally and physically burdensome for patients. Furthermore, the travel required and overall time-commitment to undergo these procedures within a clinic can result in decreased study compliance. Together these factors can confound conclusions concerning treatment efficacy. Here we will discuss how digital health can reduce these burdens when implementing therapeutic interventions to improve patient outcomes. 

CANTAB for cognitive screening in a young adult mental health unit

Mental health researcher at the University of Sydney: Brain and Mind Centre, Ashleigh Tickell, recently submitted her PhD on the feasibility of cognitive screening as standard clinical care in a young adult mental health unit. We caught up with Ashleigh to find out the outcomes of using CANTAB for her project.

CANTAB technology selected for world’s largest dementia study

We are pleased to announce our partnership with Dementias Platform UK (DPUK), the world’s largest study group in dementia research formed to accelerate the development of effective, and ultimately preventative, treatments for diseases such as Alzheimer’s.

New client signs with Cognition Kit software

We’re delighted to announce a new $0.5m contract with a major pharmaceutical company for the use of our Cognition Kit digital health software in a clinical trial.

Exploring participant-level trajectories of cognitive performance in patients with schizophrenia

Cambridge Cognition and Boehringer Ingelheim have been investigating cognitive performance among patients with schizophrenia, with a view to improving future pro-cognitive drug trial designs. Our Director of Neuroscience, Dr Kiri Granger, presented the latest findings at ISCTM and SIRS.

Pen-and-paper vs. computerised testing: which method do older adults prefer?

Exciting new research shows not only that web-based cognitive assessments are suitable for older adults but, for many, computerised assessments are actually preferable to traditional pen-and-paper tasks. 

Cognition Kit wearable technology demonstrates high compliance among patients with major depressive

​At the 2017 International CNS Summit in Boca Raton, Florida, we were pleased to release the positive results from a pilot study into the evaluation of cognition and mood using wearable technology in patients with MDD.

Join us at the CNS Summit 2017

Cambridge Cognition are attending the Collaborating for Novel Solutions (CNS) Summit: 16th-19th November 2017. 

Hogrefe becomes exclusive distributor of CANTAB in Finland

We’re pleased to announce that Hogrefe Psykologien Kustannus Oy is now an exclusive distributor of CANTAB software products for use in Finland by academic researchers and healthcare professionals.

Pre-Screening for Episodic Memory Deficits To Enrich Recruitment in Alzheimer's Disease Trials

Identifying participants in the ‘pre-clinical’ or ‘prodromal’ stage of Alzheimer's disease prior to the onset of cognitive and functional decline can be challenging, time-consuming and expensive. Can, pre-screening for episodic memory deficits enrich the recruitment of eligible participants in early Alzheimer’s disease clinical trials?

CANTAB Research Grant Supports New South Wales Brain Donor Program

Winner of the 2016 Global Prize for the CANTAB Research Grant, Toni McCrossin, Clinical Officer for the New South Wales Brain Tissue Resource Centre (NSWBTRC) explains how access to CANTAB cognitive assessments are supporting their project.

How new technologies are expanding the reach of cognitive assessment

Dr Jenny Barnett, Chief Scientific Officer for Cambridge Cognition reviews how the rise of touchscreen technology has enabled the expansion of cognitive assessment. 

Evaluating familiarity deficits related to conversion of MCI to Alzheimer’s disease

The early identification of individuals at risk of Alzheimer's Disease (AD) is of primary importance for the development of new effective interventions to stop the progression of the disease before the onset of severe neurodegeneration and clinical manifestations. 

What is cognition?

Cognition is essential for everyday functioning - here's why. 

The benefits of language and culture independent touchscreen cognitive tests

When assessing cognitive function, tests that are reliable, time and cost efficient and are comparable across cultures and languages are the key to producing accurate and valid results. There are various cognitive assessment tools out there, but what are the benefits of using language and culture independent touchscreen tests such as CANTAB?

web-based testing, wearables, voice recognition, virtual research, virtual clinical trials, technology, swm, subjective measures, stigma, social cognition, soc, smartphones, schizophrenia research, schizophrenia, research funding, remote testing, regulations, recruitment, real-world assessments, prodromal, pro-cognitive, presenteeism, preclinical, precision psychiatry, pre-clinical, physical health, personalised medicine, patient-centric, patient recruitment, patient finding, parkinson's disease, pal, ots, opinion piece, occupational health, objective measures, normative data, neurotech, neuroscience, near-patient testing, multiple sclerosis, ms, modelling, modafinil, mental wellbeing, mental health, mci, major depression, lifespan, innovate uk, ied, icosr, high frequency, healthcare, ert, epidemiology, emotion recognition, ecological momentary assessments, ebt, ebbinghaus, early alzheimer's disease, drug development, digital tools, digital health, diagnosis, depression, dementia, computerised testing, cognitive testing, cognitive science, cognitive safety, cognitive impairment, cognitive function, cognitive dysfunction, cognitive deficits, cognitive biomarkers, cognitive assessment, cognition kit, cognition, cns summit, clinical trials, clinical trial, cias, chronic pain, cgt, cantab research grant, cantab for clinical trials, cantab, brain health, brain donor program, biomarkers, awards, automatic speech recognition, autism, attention, at-home testing, asd, alzheimer's disease, affective cognition, absenteeism,